BEGIN:VCALENDAR VERSION:2.0 METHOD:PUBLISH PRODID:-//Telerik Inc.//Sitefinity CMS 15.4//EN BEGIN:VTIMEZONE TZID:W. Europe Standard Time BEGIN:STANDARD DTSTART:20251002T030000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYHOUR=3;BYMINUTE=0;BYMONTH=10 TZNAME:W. Europe Standard Time TZOFFSETFROM:+0200 TZOFFSETTO:+0100 END:STANDARD BEGIN:DAYLIGHT DTSTART:20250301T020000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYHOUR=2;BYMINUTE=0;BYMONTH=3 TZNAME:W. Europe Daylight Time TZOFFSETFROM:+0100 TZOFFSETTO:+0200 END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT DESCRIPTION:18 June 2019 14:00-15:00\n\nThe in vivo Pig-a gene mutation ass ay is based on the endogenous X-linked Pig-a gene (phosphatidylinositol N- acetylglucosaminyltransferase\, subunit A). \n\nThe Pig-a gene codes for a n N-acetyl glucosamine transferase that is involved in the biosynthesis of Glycosyl phosphatidyl inositol (GPI) anchor for tethering a variety of ma mmalian cell surface protein markers. A single mutation in the Pig-a gene results in loss of the GPI anchor and the GPI-tethered protein markers and can be detected by fluorescent antibodies against the surface markers and flow cytometric analysis to quantify marker deficient cells. \n\nThe Pig- a assay has been evaluated internationally and the data generated to date indicate that it is sensitive\, robust and has high reproducibility and tr ansferability. With this in mind\, Working Groups of the International Wor kshop on Genotoxicity Testing (IWGT) and HESI Genetic Toxicology Technical Committee (GTTC) have been working towards the development of an OECD tes ting guideline for performing the Pig-a assay in rodents\, which will allo w the Pig-a assay to be used for regulatory assessments in drug developmen t. \n\nCurrent guidance for the assessment of DNA reactive (mutagenic) imp urities in pharmaceuticals (ICH M7(R1)) has already suggested the use of t he Pig-a assay to investigate the in vivo relevance of in vitro mutagens ( Ames positive).\n\nSpeaker Biographies \;\n\nJim Whitwell\nJim has a B Sc (Hons) degree in Applied Biological Sciences from the University of Bri stol. He has more than 25 years of experience in genetic toxicology and re lated fields and currently serves as Scientific Specialist and Subject Mat ter Expert for in vitro micronucleus assays within Genetic Toxicology. \nH is areas of expertise include in vitro and in vivo chromosome aberration a nd micronucleus assays\, peripheral blood and flow in vivo micronucleus st udies and non-standard assay designs (e.g. sister chromatid exchange and m echanistic mode of action investigations).\nHe is a member of several indu stry groups and has presented at industry conferences\, as well authoring and co-authoring multiple publications in journals such as Mutation Resear ch and Mutagenesis.\nDarren Kidd\nDarren has a BSc (Hons) degree in Biolog ical Sciences from the University of Plymouth and a PhD entitled &ldquo\;I n Vitro Gene Mutation and Apoptosis&rdquo\; from the University of York. H e has more than 20 years of experience as scientist\, toxicologist and stu dy director in laboratory research and currently serves as Lead Scientist for in vitro toxicology assays within Genetic Toxicology.\nHis areas of ex pertise include in vitro micronucleus\, skin\, ocular\, phototoxicity and cytotoxicity assays\, flow cytometric applications and mechanistic investi gations.\nHe is member of several industry groups and has authored or co-a uthored dozens of posters\, presentations and publications in journals suc h as Mutation Research\, Toxicology in vitro\, Genetic Toxicology and Envi ronmental Mutagenesis\, Methods in Molecular Biology and Mutagenesis. \nRo bert Smith \;\nRobert has a MSc in Biology from the University of York . He has over 15 years of experience within genetic toxicology at Covance from working in the laboratory on standard and non-standard genotoxicity a ssays and currently serves as a Study Director within Genetic Toxicology w ith emphasis on screening as well as investigative work and method develop ment.\nHis areas of expertise include Ames\, in vitro and in vivo chromoso me aberration and micronucleus assays\, in vivo Comet and MutaMouse\, 3D s kin micronucleus and fluorescence in situ hybridisation (FISH) assays. \nH e is member of several industry groups and is the current secretary of UKE MS. He has authored or co-authored publications in Mutation Research and M utagenesis. \n\nRegistration  \;\nThis webinar is free to attend\, to register please click here. DTEND:20190618T130000Z DTSTAMP:20260517T063313Z DTSTART:20190618T120000Z LOCATION: SEQUENCE:0 SUMMARY:PSI Toxicology SIG Webinar "Pig-A Assay": UID:RFCALITEM639145963936923841 X-ALT-DESC;FMTTYPE=text/html:

18 June 2019 14:00-15:00
\n
\nThe in vivo Pig-a gene mutation assay is based on the endog enous X-linked Pig-a gene (phosphatidylinositol N-acetylglucosami nyltransferase\, subunit A).
\n
\nThe Pig-a gene codes for an N-acetyl glucosamine transferase that is involved in the biosynthe sis of Glycosyl phosphatidyl inositol (GPI) anchor for tethering a variety of mammalian cell surface protein markers. A single mutation in the P ig-a gene results in loss of the GPI anchor and the GPI-tethered prot ein markers and can be detected by fluorescent antibodies against the surf ace markers and flow cytometric analysis to quantify marker deficient cell s.
\n
\nThe Pig-a assay has been evaluated internation ally and the data generated to date indicate that it is sensitive\, robust and has high reproducibility and transferability. With this in mind\, Wor king Groups of the International Workshop on Genotoxicity Testing (IWGT) a nd HESI Genetic Toxicology Technical Committee (GTTC) have been working to wards the development of an OECD testing guideline for performing the Pig-a assay in rodents\, which will allow the Pig-a assay to be used for regulatory assessments in drug development.
\n
\nC urrent guidance for the assessment of DNA reactive (mutagenic) impurities in pharmaceuticals (ICH M7(R1)) has already suggested the use of the P ig-a assay to investigate the in vivo relevance of in vi tro mutagens (Ames positive).
\n
\nSpeaker Biograph ies \;
\n

\n

Jim Whitwell
\n< /strong>Jim has a BSc (Hons) degree in Applied Biological Sciences from th e University of Bristol. He has more than 25 years of experience in geneti c toxicology and related fields and currently serves as Scientific Special ist and Subject Matter Expert for in vitro micronucleus assays within Gene tic Toxicology.

\n

His areas of expertise include in vitro and in vi vo chromosome aberration and micronucleus assays\, peripheral blood and fl ow in vivo micronucleus studies and non-standard assay designs (e.g. siste r chromatid exchange and mechanistic mode of action investigations).

\n

He is a member of several industry groups and has presented at industry conferences\, as well authoring and co-authoring multiple publications in journals such as Mutation Research and Mutagenesis.

\n

D arren Kidd
\nDarren has a BSc (Hons) degree in Biologic al Sciences from the University of Plymouth and a PhD entitled &ldquo\;In Vitro Gene Mutation and Apoptosis&rdquo\; from the University of York. He has more than 20 years of experience as scientist\, toxicologist and study director in laboratory research and currently serves as Lead Scientist fo r in vitro toxicology assays within Genetic Toxicology.

\n

His areas of expertise include in vitro micronucleus\, skin\, ocular\, phototoxicity and cytotoxicity assays\, flow cytometric applications and mechanistic in vestigations.

\n

He is member of several industry groups and has auth ored or co-authored dozens of posters\, presentations and publications in journals such as Mutation Research\, Toxicology in vitro\, Genetic Toxicol ogy and Environmental Mutagenesis\, Methods in Molecular Biology and Mutag enesis.

\n

Robert Smith \;
\nRobe rt has a MSc in Biology from the University of York. He has over 15 years of experience within genetic toxicology at Covance from working in the lab oratory on standard and non-standard genotoxicity assays and currently ser ves as a Study Director within Genetic Toxicology with emphasis on screeni ng as well as investigative work and method development.

\n

His areas of expertise include Ames\, in vitro and in vivo chromosome aberration an d micronucleus assays\, in vivo Comet and MutaMouse\, 3D skin micronucleus and fluorescence in situ hybridisation (FISH) assays.

\n

He is memb er of several industry groups and is the current secretary of UKEMS. He ha s authored or co-authored publications in Mutation Research and Mutagenesi s.

\n


\nRegistration  \;

\n

This web inar is free to attend\, to register please click here< /a>.

END:VEVENT END:VCALENDAR